Four out of ten patients are not taking statins regularly during the 12 months after an acute coronary event

European Journal of Preventive Cardiology

Volumn 19, Issue 3, 2012, Pages 349-357

  Thornley, Simon ^a   Marshall, Roger ^a   Chan, Wing Cheuk ^b   Kerr, Andrew ^b   Harrison, Jeff ^a   Jackson, Gary ^b   Crengle, Sue ^a   Wright, Craig ^c   Wells, Sue ^a   Jackson, Rod ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b Division of Medicine Emergency and Integrated Care   (New Zealand)

^c MINISTRY OF HEALTH   (New Zealand)

Author keywords

Coronary disease; health inequality; healthcare quality; hydroxymethylglutaryl CoA reductase inhibitors; medication therapy management

Indexed keywords

ANTILIPEMIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; DRUG USE; FEMALE; FOLLOW UP; HEALTH CARE COST; HOSPITAL ADMISSION; HOSPITAL DISCHARGE; HUMAN; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEW ZEALAND; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT DURATION;

ADULT; AGED; AGED, 80 AND OVER; CORONARY DISEASE; DRUG PRESCRIPTIONS; DRUG UTILIZATION; FEMALE; GUIDELINE ADHERENCE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LOGISTIC MODELS; MALE; MIDDLE AGED; NEW ZEALAND; ODDS RATIO; PATIENT DISCHARGE; PHYSICIAN'S PRACTICE PATTERNS; PRACTICE GUIDELINES AS TOPIC; QUALITY IMPROVEMENT; QUALITY INDICATORS, HEALTH CARE; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 84865574418     PISSN: 20474873     EISSN: None     Source Type: Journal    
DOI: 10.1177/1741826711403069     Document Type: Article

References (19)

1. Baigent C, Keech A, Kearney PM, Blackwell L, Buck G, Pollicino C, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet. 2005 ; 366 (9493). 1267-1278
2. Muller-Riemenschneider F, Meinhard C, Damm K, Vauth C, Bockelbrink A, Greiner W, et al. Effectiveness of non-pharmacological secondary prevention of coronary heart disease. Eur J Cardiovasc Prev Rehabil. 2010 ; 17 (6). 688-700
3. Daskalopoulou SS, Delaney JAC, Filion KB, Brophy JM, Mayo NE, Suissa S. Discontinuation of statin therapy following an acute myocardial infarction: a population-based study. Eur Heart J. 2008 ; 29 (17). 2083-2091
4. Jackevicius CA, Mamdani M, Tu JV. Adherence with statin therapy in elderly patients with and without acute coronary syndromes. JAMA. 2002 ; 288 (4). 462-467 (Pubitemid 34787477)
5. Howell N, Trotter R, Mottram D, Rowe P. Compliance with statins in primary care. The Pharmaceutical Journal. 2004 ; 272: 23-26 (Pubitemid 38196385)
6. Grant RW, O'Leary KM, Weilburg JB, Singer DE, Meigs JB. Impact of concurrent medication use on statin adherence and refill persistence. Arch Intern Med. 2004 ; 164 (21). 2343-2348 (Pubitemid 39532245)
7. Goldenberg N, Glueck C. Efficacy, effectiveness and real life goal attainment of statins in managing cardiovascular risk. Vasc Health Risk Manag. 2009 ; 5 (1). 369-376
8. Lindgren P, Jonsson B. From 4S to IDEAL: the health economics of the statin trials. Eur J Cardiovasc Prev Rehabil. 2009 ; 16 (2). 138-143
9. Lipid modification: Cardiovascular risk assessment and the modification of blood lipids for the primary and secondary prevention of cardiovascular disease. London: National Institute for Health and Clinical Excellence ; 2008 :
10. New Zealand cardiovascular guidelines handbook: A summary resource for primary care practitioners. 2nd ed. Wellington: New Zealand Guidelines Group ; 2009 :
11. Compliance and adverse event withdrawal: their impact on the West of Scotland Coronary Prevention Study. Eur Heart J. 1997 ; 18 (11). 1718-1724
12. Salmon C, Crampton P, Atkinson J NZDep2006 Index of Deprivation User's Manual. Wellington: University of Otago ; 2007 :
13. A portrait of health: Key results of the 2006/07 New Zealand health survey. Wellington: Ministry of Health ; 2008 :
14. Schoen C, Osborn R, Doty MM, Squires D, Peugh J, Applebaum S. A survey of primary care physicians in eleven countries, 2009: perspectives on care, costs, and experiences. Health Aff. 2009 ; 28 (6). w1171 - w1183
15. Mortality and demographic data 2006. Wellington: Ministry of Health ; 2009 :
16. Pedersen TR. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Atheroscler Suppl. 2004 ; 5 (3). 81-87
17. Saha SA, Kizhakepunnur LG, Bahekar A, Arora RR. The role of fibrates in the prevention of cardiovascular disease-a pooled meta-analysis of long-term randomized placebo-controlled clinical trials. Am Heart J. 2007 ; 154 (5). 943-953 (Pubitemid 350001283)
18. Brown BG, Taylor AJ. Does ENHANCE diminish confidence in lowering LDL or in ezetimibe?. N Engl J Med. 2008 ; 358 (14). 1504-1507 (Pubitemid 351482746)
19. Mandelzweig L, Battler A, Boyko V, Bueno H, Danchin N, Filippatos G, et al. The second Euro Heart Survey on acute coronary syndromes: characteristics, treatment, and outcome of patients with ACS in Europe and the Mediterranean Basin in 2004. Eur Heart J. 2006 ; 27 (19). 2285-2293 (Pubitemid 44453571)